Comprehensive medication guide to Rinvoq XR including estimated pricing, availability information, side effects, and how to find it in stock at your local pharmacy.
Estimated Insurance Pricing
$0–$100/month copay with commercial insurance plus the Rinvoq Complete Savings Card (max $14,000 savings/year). Tier 4–5 specialty on most plans; prior authorization and step therapy (TNF inhibitor failure) required. Medicare Part D has a $2,100 annual out-of-pocket cap in 2026.
Estimated Cash Pricing
$6,500–$9,640 per month at retail pharmacies without insurance; wholesale list price (WAC) is $7,090.41 for a 30-day supply as of January 2026. No generic available. The Rinvoq Complete Savings Card can reduce costs to as little as $5/month for commercially insured patients.
Medfinder Findability Score
45/100
Summarize with AI
On this page
Rinvoq XR (upadacitinib) is a prescription oral medication manufactured by AbbVie. It belongs to the Janus kinase (JAK) inhibitor drug class — specifically, it is a second-generation selective JAK1 inhibitor. Available as extended-release tablets in 15 mg, 30 mg, and 45 mg strengths, Rinvoq XR is taken once daily by mouth, with or without food.
First approved by the FDA in August 2019 for rheumatoid arthritis, Rinvoq XR has since expanded to nine approved indications spanning rheumatology, dermatology, and gastroenterology. As of 2025, it is approved for: rheumatoid arthritis, psoriatic arthritis, atopic dermatitis, ulcerative colitis, Crohn's disease, ankylosing spondylitis, non-radiographic axial spondyloarthritis, polyarticular juvenile idiopathic arthritis, and giant cell arteritis.
Rinvoq XR is not a biologic. It is a small-molecule oral medication synthesized chemically, unlike biologic DMARDs which are derived from living cells and typically given by injection or infusion. There is currently no FDA-approved generic version of upadacitinib. A separate formulation, Rinvoq LQ (oral solution), is available for pediatric patients with PsA and pJIA but is not interchangeable with the extended-release tablets.
We have a 99% success rate finding medications, even during nationwide shortages.
Need this medication?
Rinvoq XR works by selectively blocking Janus kinase 1 (JAK1) — an enzyme that plays a central role in the JAK-STAT signaling pathway. This pathway is responsible for transmitting pro-inflammatory cytokine signals from cell surface receptors into the cell nucleus, where they trigger the production of more inflammatory chemicals.
Upadacitinib is an ATP-competitive inhibitor: it competes with adenosine triphosphate (ATP) for the binding site on JAK1, blocking kinase activity and preventing the phosphorylation and activation of STAT proteins. Without STAT activation, the inflammatory gene expression cascade is interrupted. This mechanism inhibits the signaling of key pro-inflammatory cytokines including IL-6, IL-4, IL-13, IL-12, IL-23, interferons, and GM-CSF.
Compared to earlier pan-JAK inhibitors, upadacitinib exhibits 74-fold selectivity for JAK1 over JAK2 and 58-fold selectivity over JAK3 in enzymatic assays. This selectivity is designed to reduce off-target effects while maintaining potent anti-inflammatory activity. The drug reaches peak blood concentration 2–4 hours after oral intake and achieves steady-state within 4 days.
15 mg — Extended-release tablet
Standard dose for RA, PsA, AS, nr-axSpA, GCA, pJIA; starting dose for AD
30 mg — Extended-release tablet
Dose escalation for AD if 15 mg is inadequate; maintenance dose for UC and CD
45 mg — Extended-release tablet
Induction dose for UC (8 weeks) and Crohn's disease (12 weeks)
Rinvoq XR is not on the FDA drug shortage list as of 2026. AbbVie maintains consistent manufacturing and distribution of upadacitinib. However, patients regularly report difficulty accessing the medication quickly. This is not a supply shortage — it is an access barrier problem driven by the drug's specialty medication classification, prior authorization requirements, and step therapy mandates.
Rinvoq XR is dispensed exclusively through specialty pharmacy networks (not standard retail pharmacies), and nearly all commercial and Medicare plans require prior authorization before covering it. Most plans also require documented failure of at least one TNF inhibitor before approving Rinvoq XR. These gatekeeping mechanisms — combined with the drug's $7,000+ monthly cost — create real barriers for patients who need quick access.
Use Medfinder to check real-time pharmacy inventory for Rinvoq XR near you. Medfinder shows which specialty pharmacies in your area have your specific dose (15 mg, 30 mg, or 45 mg) available today — without calling each pharmacy individually.
Rinvoq XR is not a controlled substance, so there are no DEA scheduling restrictions on who can prescribe it. Any licensed prescriber in the United States can write a prescription. However, most insurance plans require specialist prescribing or documented specialist consultation for prior authorization approval, given the drug's complexity, required pre-treatment screening, and high cost.
Rheumatologists — primary prescribers for RA, PsA, AS, nr-axSpA, GCA, and pJIA
Dermatologists — primary prescribers for atopic dermatitis (eczema)
Gastroenterologists — primary prescribers for ulcerative colitis and Crohn's disease
Primary care physicians (PCPs) — can prescribe with specialist consultation for PA approval
Nurse practitioners (NPs) and physician assistants (PAs) — full prescribing authority in most U.S. states
Telehealth prescribing of Rinvoq XR is possible in most states. Initial prescribing typically requires baseline labs completed at a local lab before or concurrent with the telehealth visit. Established patients can often manage ongoing refills and monitoring via telehealth. Telehealth rheumatology, dermatology, and gastroenterology platforms have expanded significantly, offering faster access for patients who face long waits for in-person specialist appointments.
No. Rinvoq XR (upadacitinib) is not a controlled substance. It is not scheduled by the DEA and has no federal prescribing restrictions based on controlled substance classification. Any licensed prescriber — including physicians, nurse practitioners, and physician assistants (in most states) — can write a prescription for Rinvoq XR.
However, while Rinvoq XR is not a controlled substance, it does carry an FDA Boxed Warning — the agency's most serious safety designation — for serious infections, malignancy, major adverse cardiovascular events (MACE), thrombosis, and increased all-cause mortality. Insurance companies typically require prior authorization and specialist involvement before covering it, which creates prescription access barriers despite the lack of controlled substance scheduling restrictions.
Side effects reported in ≥1% of patients in clinical trials include:
Upper respiratory tract infections (most common) — colds, sinus infections, sore throat
Herpes zoster (shingles) — more frequent than general population; Shingrix vaccine recommended before starting
Acne — commonly reported, especially in first months; typically mild
Nausea — often improves with time; taking with food may help
Cough, headache, pyrexia (fever)
Elevated CPK, elevated liver enzymes, neutropenia — detected on labs; monitored with periodic blood tests
Serious infections — including TB, bacterial, fungal, and opportunistic infections; some fatal
Malignancies — lymphoma, non-melanoma skin cancers; increased risk in smokers and those over 50 with cardiovascular risk factors
Major adverse cardiovascular events (MACE) — MI, stroke, cardiovascular death
Thrombosis — DVT, pulmonary embolism, arterial thrombosis
GI perforations, hypersensitivity reactions, embryo-fetal toxicity
Know what you need? Skip the search.
Xeljanz (tofacitinib)
Pan-JAK inhibitor (JAK1/JAK3) approved for RA, PsA, UC, AS. Generic available. Twice-daily dosing (or once-daily XR). Comparable indications with similar safety profile.
Olumiant (baricitinib)
JAK1/JAK2 inhibitor approved for RA and atopic dermatitis. Once-daily dosing (2 mg or 4 mg). Therapeutically equivalent to upadacitinib for most RA patients.
Humira (adalimumab) / biosimilars
TNF inhibitor biologic; broad indications for RA, PsA, AS, UC, Crohn's. Multiple biosimilars available at significantly lower cost. Injectable (biweekly).
Dupixent (dupilumab)
IL-4/IL-13 inhibitor biologic for atopic dermatitis, asthma, eosinophilic esophagitis. Often better covered by insurance for AD than Rinvoq XR. Biweekly injection.
Skyrizi (risankizumab)
IL-23 inhibitor biologic approved for Crohn's disease, ulcerative colitis, plaque psoriasis, PsA. IV induction then subcutaneous maintenance dosing.
Prefer Rinvoq XR? We can find it.
Other JAK inhibitors (tofacitinib, baricitinib, abrocitinib, ruxolitinib)
majorContraindicated — additive immunosuppression and serious infection risk. Never combine with another JAK inhibitor.
Biologic DMARDs (adalimumab, etanercept, infliximab, abatacept, tocilizumab, rituximab, dupilumab)
majorContraindicated — dangerous additive immunosuppression. Cannot be combined with any biologic DMARD.
Azathioprine (Imuran)
majorNot recommended — additive immunosuppression risk. Avoid combining with Rinvoq XR.
Cyclosporine
majorNot recommended — additive immunosuppression risk. Avoid combining with Rinvoq XR.
Rifampin (strong CYP3A4 inducer)
majorNot recommended — significantly reduces upadacitinib blood levels, potentially rendering it ineffective.
Strong CYP3A4 inhibitors (ketoconazole, voriconazole, clarithromycin, HIV protease inhibitors)
moderateUse caution — increases upadacitinib exposure; monitor for increased side effects. Dose adjustment may be needed.
Live vaccines (Zostavax, FluMist)
majorAvoid during therapy — increased risk of vaccine-related infection due to immune suppression. Update all live vaccines before starting Rinvoq XR.
NSAIDs (ibuprofen, naproxen)
moderateUse caution — NSAIDs may increase GI perforation risk when combined with Rinvoq XR. Use lowest effective dose.
Rinvoq XR (upadacitinib) represents one of the most significant advances in oral immunomodulation over the past decade. Its selective JAK1 inhibition, once-daily dosing, and breadth of FDA-approved indications — from RA and atopic dermatitis to Crohn's disease and giant cell arteritis — make it a versatile and clinically impactful medication.
However, its high cost ($7,090+ per month) and complex insurance requirements create real barriers for patients. Understanding the prior authorization process, enrolling in savings programs like the Rinvoq Complete Savings Card, and leveraging AbbVie's patient assistance programs are essential steps to maintaining access. Patients who are uninsured or underinsured should apply for the myAbbVieAssist program, which can provide Rinvoq XR at no cost for up to 12 months.
To find Rinvoq XR in stock at pharmacies near you and compare availability, use Medfinder — the real-time pharmacy inventory search built for patients navigating specialty medications. Always work closely with your prescriber to ensure Rinvoq XR is the right fit for your condition, health history, and individual risk profile.
Medfinder Editorial Standards
Our medication guides are researched and written to help patients make informed decisions. All content is reviewed for accuracy and updated regularly. Learn more about our standards
ChatGPT
Claude
Perplexity
Grok
Gemini